Shaji Kumar

Specialty: Hematology - Multiple myeloma trials

Location: Global

Tier: ELITE

H-Index: 110

Years Active: 0

Hospital Affiliations

• Mayo Clinic (India-origin) - Faculty

Key Publications

1. "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms." - Leukemia (2022)
2. "International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma." - J Clin Oncol (2025)
3. "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee." - Blood (2022)
4. "Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology." - J Natl Compr Canc Netw (2023)
5. "Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial." - Lancet Oncol (2021)

Knowledge Graph Relationships

Shaji Kumar is a Hematology - Multiple myeloma trials specialist affiliated with Mayo Clinic (India-origin). Authored 5 scholarly articles.